Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS-3 long-term extension study of mirikizumab in plaque psoriasis
jRCT2080224141Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Primary endpoints: Long-term safety of mirikizumab and Maintenance of treatment effect. Started Nov 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2080224141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224141.